FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody or its antigen-binding fragment that specifically bind human CD19. A chimeric antigen receptor containing the specified antibody; a nucleic acid molecule encoding the specified antibody; a cell containing the specified nucleic acid molecule are also disclosed. A method for the treatment of a medical condition characterized by CD19 expression, using the specified antibody; a method for the control of T-cells to destroy target cells expressing CD19 are disclosed.
EFFECT: invention allows for the effective treatment of a medical condition characterized by CD19 expression.
32 cl, 6 ex, 9 tbl, 15 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NEW ANTI-CD19 ANTIBODIES | 2018 |
|
RU2791445C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| COMBINATION OF CD19 ANTIBODY AND BRUTON TYROSINE KINASE INHIBITOR AND THEIR APPLICATION | 2016 |
|
RU2756010C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| BISPECIFIC ANTIBODY | 2020 |
|
RU2814713C2 |
| HUMANISED HUMAN CD19 ANTIBODIES AND METHODS FOR USE THEREOF | 2016 |
|
RU2731156C1 |
| C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
| CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND THEIR USE | 2018 |
|
RU2780020C2 |
| NEW BISPECIFIC POLYPEPTIDE COMPLEXES AGAINST CD3/CD19 | 2018 |
|
RU2788127C2 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
